Newsfeeds - Spark Newswire

4 minute read

The Daily Biotech Pulse: Restricted Authorization For Pfizer’s COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data

Today, 5:15 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22)

ABCL

6 minute read

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs

By Shanthi Rexaline

Today, 5:15 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)

ABEO

6 minute read

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data

By Shanthi Rexaline

Today, 5:15 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)

ABSI

1 minute read

Analyst Ratings

Where TCR2 Therapeutics Stands With Analysts

By Benzinga Insights

Today, 5:15 AM

Within the last quarter, TCR2 Therapeutics (NASDAQ:TCRR) has observed the following analyst ratings:

TCRR

1 minute read

Truist Securities Maintains Buy on TCR2 Therapeutics, Lowers Price Target to $29

By vishwanath@benzinga.com

Today, 5:15 AM

Truist Securities analyst Asthika Goonewardene maintains TCR2 Therapeutics (NASDAQ:TCRR) with a Buy and lowers the price target from $40 to $29.

TCRR

1 minute read

10 Biggest Price Target Changes For Monday

By Lisa Levin

Today, 5:15 AM

Barclays boosted Upstart Holdings, Inc. (NASDAQ: UPST) price target from $230 to $345. Upstart shares fell 2.8% to $294.87 in pre-market trading.

1 minute read

Wedbush Downgraded TCR2 Therapeutics to Neutral, Lowered Price Target to $11 – Report Published on September 17, 2021

By Benzinga Newsdesk

Today, 5:15 AM

Wedbush analyst David Nierengarten downgraded TCR2 Therapeutics (NASDAQ:TCRR) from Outperform to Neutral and lowered the price target from $45 to $11, report published on September 17, 2021.

TCRR

1 minute read

HC Wainwright & Co. Maintains Buy on TCR2 Therapeutics, Lowers Price Target to $25

By Benzinga Newsdesk

Today, 5:15 AM

HC Wainwright & Co. analyst Robert Burns maintains TCR2 Therapeutics (NASDAQ:TCRR) with a Buy and lowers the price target from $37 to $25.

TCRR

4 minute read

48 Biggest Movers From Friday

By Lisa Levin

Today, 5:15 AM

Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer.

AKYA

2 minute read

Mid-Afternoon Market Update: Nasdaq Down 1%; Protagonist Therapeutics Shares Plummet

By Lisa Levin

Today, 5:15 AM

Toward the end of trading Friday, the Dow traded down 0.47% to 4,587.22 while the NASDAQ fell 1.05% to 15,023.11. The S&P also fell, dropping 0.85% to 4,435.65.

AZN